Trial · NCT01972568
Results by group69
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 69
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Screening Visit as Baseline | Atacicept 75 mg | 57.8 | percentage of subjects | ||
| Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Screening Visit as Baseline | Atacicept 150 mg | 53.8 | percentage of subjects | ||
| Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Screening Visit as Baseline | Placebo | 44.0 | percentage of subjects | ||
Percentage of Subjects at Week 24 Whose Prednisone-Equivalent Corticosteroid (CS) Dose Reduced From Screening by >=25% and to a Dose of =<7.5mg/Day, and no British Isles Lupus Assessment Group (BILAG) A or 2B Flare in Disease Activity | Atacicept 75 mg | 17.9 | percentage of subjects | ||
Percentage of Subjects at Week 24 Whose Prednisone-Equivalent Corticosteroid (CS) Dose Reduced From Screening by >=25% and to a Dose of =<7.5mg/Day, and no British Isles Lupus Assessment Group (BILAG) A or 2B Flare in Disease Activity | Atacicept 150 mg | 11.3 | percentage of subjects | ||
Percentage of Subjects at Week 24 Whose Prednisone-Equivalent Corticosteroid (CS) Dose Reduced From Screening by >=25% and to a Dose of =<7.5mg/Day, and no British Isles Lupus Assessment Group (BILAG) A or 2B Flare in Disease Activity | Placebo | 18.9 | percentage of subjects | ||
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 75 mg | Very much or much improved | 57.8 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 150 mg | Very much or much improved | 53.8 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Placebo | Very much or much improved | 46.0 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 75 mg | Minimally improved or no change or minimally worse | 39.2 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 150 mg | Minimally improved or no change or minimally worse | 44.2 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Placebo | Minimally improved or no change or minimally worse | 46.0 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 75 mg | Much or very much worse | 2.0 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 150 mg | Much or very much worse | 1.0 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Placebo | Much or very much worse | 6.0 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 75 mg | Missing | 1.0 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Atacicept 150 mg | Missing | 1.0 | percentage of subjects | |
| Percentage of Subjects With Patient Global Impression of Change (PGIC) Categories at Week 24 | Placebo | Missing | 2.0 | percentage of subjects | |
| Change From Screening in Prednisolone-Equivalent Corticosteroid (CS) Daily Dose at Week 24 | Atacicept 75 mg | -2.64 | Standard Deviation 6.106 | mg per day | |
| Change From Screening in Prednisolone-Equivalent Corticosteroid (CS) Daily Dose at Week 24 | Atacicept 150 mg | -1.87 | Standard Deviation 4.653 | mg per day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01972568/results